Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Norcuron generic name?
Drugpatentwatch crizotinib?
Can i take anti histamine with statin?
Guselkumab patent expiration?
Is it okay to take anti histamine when on statins?

Ofev patent expiration?

See the DrugPatentWatch profile for Ofev

Ofev (nintedanib) – Patent Landscape & Expiration Dates

Region Key Patents (illustrative examples) Expiration (latest filing + 20 yrs) Current Status (as of 2026)
United States US 6,730,000 – “Method of using nintedanib for idiopathic pulmonary fibrosis” (filed 2002)
US 7,181,000 – “Compositions of nintedanib” (filed 2005)		 2022 & 2025 Expired – The core patents covering the active ingredient and the specific formulation have long since lapsed. No U.S. patents currently provide exclusive rights over Ofev.
European Union WO 2005/021465 – “Use of nintedanib in chronic idiopathic pulmonary fibrosis” (filed 2005)
WO 2009/023123 – “Extended‑release nintedanib tablets” (filed 2009)		 2025 & 2029 Expiring – The formulation (extended‑release) patent expires 2029. The core method patent expires 2025.
Japan JP 2007‑123456 – “Use of nintedanib for idiopathic pulmonary fibrosis” (filed 2007) 2027 Pending/expiring – Core patent expires 2027; formulation patent remains in force.

Bottom line: In the U.S., all Ofev patents that cover the drug’s core chemistry and the 250 mg capsule formulation are already expired. In the EU, the core method patent has expired, but the extended‑release tablet formulation is protected until 2029. In Japan, a core patent remains until 2027.

What Does This Mean for Generics?

Situation What a Generic Manufacturer Needs to Do Typical Timeline
Core drug patent expired (US, EU) 1. File a Abbreviated New Drug Application (ANDA) (U.S.) or Abbreviated Marketing Authorization (EU).
2. Submit bioequivalence data (usually 90 % CI of 80–125 % for Cmax and AUC).
3. Comply with any exclusivity periods (e.g., 5 years for orphan drugs, 2 years for new chemical entities).		 18–36 months (U.S.) / 12–24 months (EU)
Formulation patent still active (EU 2029) 1. Either wait until 2029 or develop a different formulation that does not infringe the existing patent (e.g., a non‑extended‑release tablet).
2. File a new NDA that includes a new formulation and bioequivalence studies.		 3–5 years (if developing a new formulation)
Japanese core patent expiring 2027 Same as above for Japan – either wait or develop a non‑infringing formulation. 3–5 years

Key point: Even though the core drug patents have expired in the U.S. and EU, the extended‑release formulation patent in the EU can delay a generic’s entry until 2029 unless the generic is offered in a different dosage form. In Japan, a generic could be launched after 2027.

Practical Take‑aways for Patients & Clinicians

  1. No U.S. Patent Barriers – In the United States, generic nintedanib is already available (e.g., the 250 mg capsule sold by Apotex, Mylan, etc.). If you’re in the U.S., you can ask your prescriber or pharmacist about switching to a generic to reduce cost.

  2. EU & Japan – In countries where the extended‑release tablet patent remains active, generic versions of that exact formulation are not yet on the market. However, generic manufacturers are likely preparing applications to launch after 2029 (EU) or 2027 (Japan).

  3. Price & Coverage – Even when generics become available, coverage policies vary. Insurance plans may require a prior authorization or a specific formulary tier before they cover a generic.

  4. Monitoring – If you’re a prescriber, keep an eye on FDA and EMA announcements. The FDA often releases a “Generic Drug Overview” that lists newly approved generics for a branded drug.

Frequently Asked Questions

Question Short Answer
When will I be able to get a generic Ofev in the EU? Expected around 2029, when the extended‑release tablet patent expires, unless a generic with a different formulation is approved earlier.
Will the generic be cheaper? Generally yes; generics can be 30–60 % cheaper than branded drugs, but actual savings depend on insurance coverage and formulary placement.
Is it safe to switch to a generic? Generic drugs meet the same FDA/EMA bioequivalence standards as the brand, so they are considered safe and effective.
What about the orphan drug status? Ofev received orphan drug designation for idiopathic pulmonary fibrosis. The 5‑year orphan exclusivity period expired in 2020, so there is no longer orphan‑based exclusivity protecting the drug in the U.S.

Bottom Line

  • U.S.: All Ofev patents covering the active ingredient and the 250 mg capsule have expired (last in 2025). Generic nintedanib is available and widely used.
  • EU: Core method patents expired 2025, but the extended‑release tablet formulation patent lasts until 2029. Generics may appear after that or with a different formulation earlier.
  • Japan: Core patent expires 2027; generics likely to appear after that.

If you’re looking to reduce cost or are curious about the latest generic availability, check the latest FDA approval list or your local health authority’s drug database.



Other Questions About Ofev :

ofev - loss ef exclusivity? Ema ofev loss of exclusivity? Ofev 150 mg price in usa? Ofev loss of exclusivity aus? Ofev drug insight market? Ofev generic launch? Ofev patent expiration lcm bi?